Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I randomized double-blind placebo-controlled study of live-attenuated RSV*G vaccine in healthy adults
NL-OMON47495Phase 1Active, not recruiting
- Sponsor
- Intravacc
- Start
- May 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RSVdG vaccine in respiratory syncytial virus disease (RSV) (2 arms), sponsored by Intravacc. Primary endpoints: Safety and tolerability, Systemic and mucosal immunogenicity and 2 more. Started May 2018; status: active, not recruiting.
02
Drugs
RSVdG vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON47495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47495.